Organon Completes Spin-Out From Merck With Five Biosimilars
Adalimumab Recently Launched In Australia And Canada
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
You may also be interested in...
Despite commercial success in biosimilars, Pfizer said it is more interested in investing in innovative therapeutics.
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.